

10/03/636

***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:15:16 ON 05 JAN 2004

=> file medline biosis caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 15:15:44 ON 05 JAN 2004

FILE 'BIOSIS' ENTERED AT 15:15:44 ON 05 JAN 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CAPLUS' ENTERED AT 15:15:44 ON 05 JAN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s modif#####(10a) 2'-OH(10a)RNA

MISMATCHED QUOTE ' 2'-OH'

Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s modif#####(10a)2-OH(10a)RNA

L1 12 MODIF#####(10A) 2-OH(10A) RNA

=> s l1 and isolat###

L2 2 L1 AND ISOLAT###

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 2 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 1-2 bib ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:881292 CAPLUS

DN 134:39163

TI Isolation of RNA by differential labeling of the ribose moiety
with an affinity label

IN Goldsborough, Andrew Simon

PA Cyclops Genome Sciences Ltd., UK

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000075302	A2	20001214	WO 2000-GB1684	20000502
	WO 2000075302	A3	20010426		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	WO 2001094626	A1	20011213	WO 2000-GB1683	20000502
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,			

CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1177281 A2 20020206 EP 2000-929666 20000502
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

EP 1196631 A1 20020417 EP 2000-929665 20000502
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 2003039985 A1 20030227 US 2001-11495 20011026

PRAI GB 1999-10154 A 19990430
 GB 1999-10156 A 19990430
 GB 1999-10157 A 19990430
 GB 1999-10158 A 19990430
 WO 2000-GB1683 W 20000502
 WO 2000-GB1684 W 20000502

AB A method of purifying RNA from a mixt. of nucleic acids including DNA that makes use of the difference in the sugar moiety of the nucleic acid backbone is described. A sample is treated with a reactant capable of covalently modifying the 2'-OH position of the ribose rings of the RNA under conditions so that a proportion of the 2'-OH positions of the ribose rings bear a substituent followed by sepn. of RNA from other contaminants on the basis of a property of the substituent. The use of alkyl groups to modify the backbone of the RNA for capture on a hydrophobic surface, such as a modified agarose, after salting out with ammonium sulfate is demonstrated.

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:816043 CAPLUS

DN 130:77053

TI High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)

IN Janjic, Nebojsa; Gold, Larry

PA Nexstar Pharmaceuticals, Inc., USA

SO U.S., 64 pp., Cont.-in-part of U.S. 5,475,096.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 125

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5849479	A	19981215	US 1994-233012	19940425
	US 5475096	A	19951212	US 1991-714131	19910610
	EP 786469	A2	19970730	EP 1997-200035	19910610
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 112141	A1	19980405	IL 1991-112141	19910611
	US 5496938	A	19960305	US 1992-964624	19921021
	CA 2169536	AA	19950316	CA 1994-2169536	19940908
	WO 9507364	A1	19950316	WO 1994-US10306	19940908
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9476865	A1	19950327	AU 1994-76865	19940908
	AU 692469	B2	19980611		
	EP 724647	A1	19960807	EP 1994-927409	19940908
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09502354	T2	19970311	JP 1994-508834	19940908

	US 5811533	A	19980922	US 1995-447169	19950519
	US 5789163	A	19980804	US 1995-487425	19950607
	US 6168778	B1	20010102	US 1997-870930	19970606
	US 2003198989	A1	20031023	US 2003-408085	20030403
	US 2003176680	A1	20030918	US 2003-409565	20030407
PRAI	US 1990-536428	B2	19900611		
	US 1991-714131	A2	19910610		
	US 1992-964624	A2	19921021		
	EP 1991-912753	A3	19910610		
	IL 1991-98456	A3	19910611		
	US 1993-117991	A	19930908		
	US 1993-134028	A	19931007		
	US 1994-199507	A	19940222		
	US 1994-205515	B2	19940303		
	US 1994-233012	A	19940425		
	US 1994-234997	A	19940428		
	WO 1994-US10306	W	19940908		
	US 1995-409442	A1	19950324		
	US 1995-412110	A1	19950327		
	US 1995-428964	B1	19950425		
	US 1995-447169	A2	19950519		
	US 1995-469609	A1	19950606		
	US 1998-143190	A1	19980827		
	US 1998-156824	B1	19980918		
	US 2000-502344	A1	20000210		
	US 2001-860474	A1	20010518		
	US 2001-37986	A1	20011018		

AB This invention describes the isolation and characterization of binding properties of a set of high-affinity RNA ligands to vascular endothelial growth factor (VEGF). These ligands were selected from an initial pool of about 1014 RNA mols. randomized at thirty contiguous positions. The evolved RNA ligands bind VEGF with affinities in the low nanomolar range. Also described are modified RNA ligands to VEGF. Such modified RNA ligands may be prepd. after the identification of 2'-OH RNA ligands or by performing SELEX using a candidate mixt. of modified RNAs. For example, 2'-NH2 pyrimidine RNA ligands to VEGF are described. The present invention includes the method of identifying nucleic acid ligands and ligand sequences to VEGF.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

10/031,636

Freeform Search

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

Display: 10 Documents in Display Format: Starting with Number 1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Interrupt

Search History

DATE: Monday, January 05, 2004 [Printable Copy](#) [Create Case](#)Set Name Query

side by side

Hit Count Set Name

result set

DB=PGPB; PLUR=YES; OP=ADJ

L2 US-20030039985-A1.did. 1 L2

DB=USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

L1 modify\$3 near5 2-OH near5 RNA 1 L1

END OF SEARCH HISTORY